4.4 Article

Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets

期刊

NEUROEPIDEMIOLOGY
卷 43, 期 3-4, 页码 194-205

出版社

KARGER
DOI: 10.1159/000367970

关键词

Calibration; Neuropsychological performance; Alzheimer's disease

资金

  1. National Institutes of Health [R03 AG045494, R01 HG002213, K24 AG027841, U01 AG032984]
  2. Alzheimer's Association
  3. NIA [U01 AG06781]
  4. NHGRI [U01 HG006375]
  5. Alzheimer's Association [MNIRG-11-205368]
  6. BYU Gerontology Program
  7. NIH [R01 AG11380, R01 AG021136, P30 NS069329-01, R01 AG042611, P30AG10161, R01AG17917]
  8. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  9. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  10. National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
  11. Alzheimer's Drug Discovery Foundation
  12. BioClinica, Inc.
  13. Biogen Idec Inc.
  14. Bristol-Myers Squibb Company
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. F. Hoffmann-La Roche Ltd.
  19. Genentech, Inc.
  20. GE Healthcare
  21. Innogenetics, N.V.
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC
  24. Johnson & Johnson Pharmaceutical Research & Development LLC
  25. Medpace, Inc.
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC
  28. NeuroRx Research
  29. Novartis Pharmaceuticals Corporation
  30. Pfizer Inc.
  31. Piramal Imaging
  32. Servier
  33. Synarc Inc.
  34. Takeda Pharmaceutical Company
  35. Canadian Institutes of Health Research
  36. [U01 AG016976]
  37. NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002213, U01HG006375] Funding Source: NIH RePORTER
  38. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS069329] Funding Source: NIH RePORTER
  39. NATIONAL INSTITUTE ON AGING [P30AG010161, P30AG010129, R01AG017917, RF1AG015819, R03AG045494, K01AG030514, U01AG024904, R01AG042611, K25AG041906, U01AG006781, U01AG032984, R01AG021136, K24AG027841, R01AG011380, U01AG016976] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background: We sought to identify optimal approaches by calibrating longitudinal cognitive performance across studies with different neuropsychological batteries. Methods: We examined four approaches to calibrate cognitive performance in nine longitudinal studies of Alzheimer's disease (AD) (n = 10,875): (1) common test, (2) standardize and average available tests, (3) confirmatory factor analysis (CFA) with continuous indicators, and (4) CFA with categorical indicators. To compare precision, we determined the minimum sample sizes needed to detect 25% cognitive decline with 80% power. To compare criterion validity, we correlated cognitive change from each approach with 6-year changes in average cortical thickness and hippocampal volume using available MRI data from the AD Neuroimaging Initiative. Results: CFA with categorical indicators required the smallest sample size to detect 25% cognitive decline with 80% power (n = 232) compared to common test (n = 277), standardize- and-average (n = 291), and CFA with continuous indicators n = 315) approaches. Associations with changes in biomarkers changes were the strongest for CFA with categorical indicators. Conclusions: CFA with categorical indicators demonstrated greater power to detect change and superior criterion validity compared to other approaches. It has wide applicability to directly compare cognitive performance across studies, making it a good way to obtain operational phenotypes for genetic analyses of cognitive decline among people with AD. (C) 2014 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据